DEA Considers New Importer for Psilocybin and Other Controlled Substances
Published Date: 5/20/2025
Notice
Summary
Patheon API Inc. wants to become an official importer of certain controlled substances, including psilocybin and psilocyn. If you’re a registered manufacturer or interested party, you have until June 20, 2025, to share your thoughts or ask for a hearing. This move could impact companies dealing with these substances and involves a formal review process with no immediate cost changes announced.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 1 costs, 1 mixed.
Import Limited to Reference Standards; No Finished Drugs
The company plans to import psilocybin and psilocyn only as reference standards for research and development as part of active pharmaceutical ingredient (API) manufacturing, and "no other activities for these drug codes are authorized for this registration." The authorization will not cover importation of Food and Drug Administration‑approved or non‑approved finished dosage forms for commercial sale.
Application to Import Psilocybin and Psilocyn
Patheon API Inc. applied on January 16, 2025 to be registered as an importer of psilocybin (code 7437) and psilocyn (code 7438), which are listed as Schedule I controlled substances. The application requests authority to import these substances under the Drug Enforcement Administration registration process.
Comment and Hearing Deadline: June 20, 2025
Registered bulk manufacturers of the affected basic classes, and applicants, may submit electronic comments, objections, or written requests for a hearing on this application on or before June 20, 2025 via https://www.regulations.gov or by sending hearing requests to the DEA address listed in the notice.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-23508, Dave Allen Wright, M.D.; Decision and Order
Dr. Dave Allen Wright from Ohio lost his DEA registration because he no longer has permission to handle controlled substances in Ohio and didn’t respond to the DEA’s notices. Since he didn’t ask for a hearing, the DEA officially revoked his registration, meaning he can’t legally prescribe or manage controlled drugs anymore. This decision is final as of November 2026 and affects Dr. Wright’s ability to work with controlled substances.
2026-23513, Kyndahl D. Bertram, D.O.; Decision and Order
Dr. Kyndahl D. Bertram lost her DEA registration because she no longer has permission to handle controlled substances in Virginia. She didn’t ask for a hearing to challenge this, so the DEA officially revoked her registration, which expired on July 31, 2026. This means she can’t legally prescribe or manage controlled drugs anymore, effective immediately.
Previous / Next Documents
Previous: 2025-08987, Ferrosilicon From Kazakhstan: Amended Final Countervailing Duty Determination; Ferrosilicon From Brazil, Kazakhstan, and Malaysia: Countervailing Duty Orders
The U.S. government is putting extra taxes on ferrosilicon imports from Brazil, Kazakhstan, and Malaysia because these countries got unfair help from their governments. They fixed a small mistake in the Kazakhstan case to keep things fair. These new rules started on May 20, 2025, and will affect companies importing ferrosilicon, making prices more balanced for U.S. producers.
Next: 2025-08991, Open Meeting of the Taxpayer Advocacy Panel's Special Projects Committee
The IRS is hosting a virtual meeting on June 12, 2025, to hear your ideas on making tax services better and easier for everyone. If you want to join or speak up, sign up by June 8 to get the details. This is a great chance for taxpayers to help shape how the IRS works without spending a dime or leaving home!